2009
DOI: 10.1002/jps.21752
|View full text |Cite
|
Sign up to set email alerts
|

Characterisation of the thermal, spectroscopic and drug dissolution properties of mefenamic acid and polyoxyethylene–polyoxypropylene solid dispersions

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

2
18
0

Year Published

2012
2012
2017
2017

Publication Types

Select...
8

Relationship

2
6

Authors

Journals

citations
Cited by 33 publications
(20 citation statements)
references
References 35 publications
(32 reference statements)
2
18
0
Order By: Relevance
“…In addition, PEO has been shown to form miscible blends through interactions with drugs that contain proton donor groups and thus has the potential to form stable solid dispersions 11. Moreover, previous work by our group and others in this area has shown that semicrystalline polymers [PEO, Pluronic (copolymer of PEO) and ethylene vinyl acetate] have the potential to accommodate drug molecules within amorphous domains 12–14. Therefore, within this study, we wanted to examine if extrusion significantly affected the amorphous/crystalline ratio within PEO and if this influenced the ability of PEO to accommodate bicalutamide (BL), thus altering the performance of the extruded drug dispersion.…”
Section: Introductionmentioning
confidence: 99%
“…In addition, PEO has been shown to form miscible blends through interactions with drugs that contain proton donor groups and thus has the potential to form stable solid dispersions 11. Moreover, previous work by our group and others in this area has shown that semicrystalline polymers [PEO, Pluronic (copolymer of PEO) and ethylene vinyl acetate] have the potential to accommodate drug molecules within amorphous domains 12–14. Therefore, within this study, we wanted to examine if extrusion significantly affected the amorphous/crystalline ratio within PEO and if this influenced the ability of PEO to accommodate bicalutamide (BL), thus altering the performance of the extruded drug dispersion.…”
Section: Introductionmentioning
confidence: 99%
“…In the Eudragit/Lutrol/drug extrudate, although small peaks in the PXRD of the drug disappeared because of partial loss of crystallinity, the main peaks at 6.8°, 12.7°, 13.5°, 18.9°, 20.4°, 21.9°, 25.1°, 28.7° and 35.3° are still there, indicating presence of crystalline phase of the drug dispersed in the amorphous polymer/plasticiser matrix. Loss of crystallinity of mefenamic acid and carbamazepine in solid dispersions with polyoxyethylene‐polyoxypropylene copolymers has already been described …”
Section: Resultsmentioning
confidence: 82%
“…Loss of crystallinity of mefenamic acid and carbamazepine in solid dispersions with polyoxyethylene-polyoxypropylene copolymers has already been described. [29,30]…”
Section: Powder X-ray Diffractionmentioning
confidence: 99%
“…Previous studies have shown that an active substance preferentially occupies the amorphous regions of polymeric matrices [22]. This is comparable to lipid matrices where an active compound would be primarily solubilized in oily microdomains, while the active compound solubility in crystalline lipid is expected to be rather poor [23].…”
Section: Study Of the Raw Materialsmentioning
confidence: 95%